翰宇药业：利拉鲁肽原料药获韩国MFDS受理

Core Viewpoint - Hanyu Pharmaceutical's subsidiary has received approval for liraglutide active pharmaceutical ingredient from the Korean Ministry of Food and Drug Safety, which is expected to enhance the company's competitiveness and positively impact future performance and industry position [1] Company Summary - Hanyu Pharmaceutical's subsidiary, Hanyu Pharmaceutical (Wuhan) Co., Ltd., has had its liraglutide active pharmaceutical ingredient approved by the Korean Food and Drug Safety [1] - Liraglutide is a GLP-1 analog with multiple physiological functions, including promoting insulin secretion in a glucose-dependent manner, protecting pancreatic beta cells, and delaying gastric emptying to reduce appetite [1] Industry Summary - The approval of liraglutide is anticipated to boost the company's competitive edge within the industry, potentially leading to growth in future performance and an improved industry standing [1]